Acurx Pharmaceuticals, Inc. has made a significant change to its corporate governance by amending its bylaws. On October 29, 2026, the company’s Board of Directors approved a new quorum requirement for stockholder meetings, reducing it from a majority to one-third of the voting power.

This amendment is designed to streamline the decision-making process during stockholder meetings, allowing Acurx to conduct business more efficiently. The adjustment reflects a strategic move that may enhance the company’s ability to respond quickly to industry demands and operational needs.

Background

Acurx Pharmaceuticals, Inc. is a Delaware-based company engaged in the development of pharmaceutical preparations. It operates under the ticker symbol ACXP on the Nasdaq exchange. The company is classified under the Standard Industrial Classification (SIC) code 2834, which pertains to pharmaceutical preparations. Acurx has been active in filing various reports with the SEC, including recent 8-K filings on October 29, 2026, and October 16, 2026.

What the Filing Says

The SEC filing states, “On October 29, 2026, the Board of Directors of Acurx Pharmaceuticals, Inc. approved and adopted, effective as of that date, an amendment to the Company’s Bylaws. The Amendment reduces the quorum at all meetings of the Company’s stockholders for the transaction of business… to one-third (33⅓%) of the voting power of the stock outstanding and entitled to vote at the meeting.” This change is expected to facilitate more efficient governance.

Impact

The amendment may affect Acurx’s stockholders and management by enabling a more agile decision-making process. This change could also influence how other companies in the pharmaceutical preparations industry approach their governance structures, potentially leading to similar amendments across the sector.

What's Next

The filing does not say what happens next.